We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 20, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. (LLY - Free Report) , PepsiCo, Inc. (PEP - Free Report) and Morgan Stanley (MS - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Eli Lilly, PepsiCo and Morgan Stanley
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., PepsiCo, Inc. and Morgan Stanley. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the last two years (+101.3% vs. +16.6%). The Zacks analyst believes that the company has seen unparalleled success with its GLP-1 drugs, Mounjaro and Zepbound. In the past couple of years, Lilly has received approvals for several new drugs and witnessed pipeline and regulatory success.
However, declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds.
PepsiCo’s shares have underperformed the Zacks Beverages – Soft drinks industry over the past year (-4.9% vs. +4.0%). The Zacks analyst believes that largely due to challenges in its North American operations since the start of 2024 that includes reduced consumer demand and product recalls in the QFNA segment, the company has underperformed over the past year. Additionally, adverse currency rates continue to pose challenges.
Yet, it is well-poised to benefit from strength and resilience in core categories, diversified portfolio, modernized supply chain, improved digital capabilities and flexible go-to-market distribution systems. The company's international business continues to hallmark its overall performance.
Shares of Morgan Stanley have outperformed the Zacks Financial - Investment Bank industry over the last six months (+33.4% vs. +22.8%). Per the Zacks analyst, a gradual revival in the investment banking (IB) business and a solid IB pipeline are expected to support its financials. Efforts to become less dependent on capital-markets-driven revenues, inorganic expansion/strategic alliance and high rates will also aid the top line.
However, operating expenses are likely to stay elevated amid business expansion efforts. The ambiguity of the performance of the capital markets is a concern and might hurt the Institutional Securities segment’s prospects.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley
For Immediate Release
Chicago, IL – November 20, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. (LLY - Free Report) , PepsiCo, Inc. (PEP - Free Report) and Morgan Stanley (MS - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Eli Lilly, PepsiCo and Morgan Stanley
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., PepsiCo, Inc. and Morgan Stanley. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the last two years (+101.3% vs. +16.6%). The Zacks analyst believes that the company has seen unparalleled success with its GLP-1 drugs, Mounjaro and Zepbound. In the past couple of years, Lilly has received approvals for several new drugs and witnessed pipeline and regulatory success.
However, declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds.
(You can read the full research report on Eli Lilly here >>>)
PepsiCo’s shares have underperformed the Zacks Beverages – Soft drinks industry over the past year (-4.9% vs. +4.0%). The Zacks analyst believes that largely due to challenges in its North American operations since the start of 2024 that includes reduced consumer demand and product recalls in the QFNA segment, the company has underperformed over the past year. Additionally, adverse currency rates continue to pose challenges.
Yet, it is well-poised to benefit from strength and resilience in core categories, diversified portfolio, modernized supply chain, improved digital capabilities and flexible go-to-market distribution systems. The company's international business continues to hallmark its overall performance.
(You can read the full research report on PepsiCo here >>>)
Shares of Morgan Stanley have outperformed the Zacks Financial - Investment Bank industry over the last six months (+33.4% vs. +22.8%). Per the Zacks analyst, a gradual revival in the investment banking (IB) business and a solid IB pipeline are expected to support its financials. Efforts to become less dependent on capital-markets-driven revenues, inorganic expansion/strategic alliance and high rates will also aid the top line.
However, operating expenses are likely to stay elevated amid business expansion efforts. The ambiguity of the performance of the capital markets is a concern and might hurt the Institutional Securities segment’s prospects.
(You can read the full research report on Morgan Stanley here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.